[{"orgOrder":0,"company":"Santa Ana Bio","sponsor":"GV","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Series B Financing","leadProduct":"SAB01","moa":"","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Santa Ana Bio","amount2":0.13,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0.13,"dosageForm":"","sponsorNew":"Santa Ana Bio \/ GV","highestDevelopmentStatusID":"5","companyTruncated":"Santa Ana Bio \/ GV"}]

Find Clinical Drug Pipeline Developments & Deals by Santa Ana Bio

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The Pharmacy Technology
                          Not Confirmed
                          The Pharmacy Technology
                          Not Confirmed

                          Details : The financing aims to find the advanced pipeline of Santa Ana Bio, which includes SAB01, c-Kit inhibitor. Currently, it is being evaluated for the treatment of urticaria.

                          Brand Name : SAB01

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 13, 2024

                          Lead Product(s) : SAB01

                          Therapeutic Area : Dermatology

                          Highest Development Status : IND Enabling

                          Sponsor : GV

                          Deal Size : $125.0 million

                          Deal Type : Series B Financing

                          blank